Clinical CRO ICRC-Weyer Ready for Increase in Advanced Therapy Trials

The clinical contract research organization (CRO) ICRC-Weyer GmbH, based in Berlin, Germany, has announced that the company is prepared for the increasing number of Advanced Therapy trials, a trend that is expected to continue for the next 10 to 15 years.

Berlin, Germany, September 27, 2012 --( ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in discussions on potential co-operations with other participants.

The event demonstrated the rapid and versatile development in the area of regenerative medicine. One of the attendees, Dr. Iris Hardewig, Head of Medical Writing & Scientific Consulting at ICRC-Weyer GmbH, said: "Due to new regulations in the field of Advanced Therapy Medicinal Products (ATMP) a wave of registrations for such can be expected in the coming 10 to 15 years. Hence, the number of clinical trials for these products will increase significantly. As a medium-sized CRO providing specialized and flexible services to small biotech companies, ICRC-Weyer can deliver high-quality results for ATMP trials and contribute to this promising development."

Just recently, ICRC-Weyer announced that the company has extended its clinical monitoring services portfolio to monitoring for trials in the area of stem cell research and thus being able to serve the demands of the global pharmaceutical industry in the growing field of regenerative medicine.

"The engaged discussions of our team members with different participating companies show that there is a lively interest in high quality clinical services in the area of regenerative medicine," Dr. Hardewig continues, "one reason being the initiation of the 7th Framework Programme (FP7) by the EU which provides an important source for funding early clinical development of advanced therapies. The program has paved the way for further research in Europe in the area of ATMP."

About the NanoKTN event:
The networking event was hosted by UK Nanotechnology Knowledge Transfer Network (NanoKTN) and BioTOP Berlin-Brandenburg. The meeting is designed to bring a selection of the UK’s leading companies and academics developing nano-structured materials and biomaterials for use in tissue engineering and regenerative medicine, to meet with centres of research excellence in Berlin.

About FP7:
The Seventh Framework Programme for Research and Technological Development (FP7) is the EU's main instrument for funding research in Europe. The program supports research in selected priority areas - the aim being to make, or keep, the EU as a world leader in those sectors.

About ICRC-Weyer:
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.

ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.
ICRC-Weyer GmbH
J. Daniel Weyer
49 30 403937-0